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Abstract
Background: There is growing evidence that adiponectin, a physiologically active polypeptide secreted by
adipocytes, controls not only adipose tissue but also bone metabolism. However, a role for adiponectin in bone
development remains controversial.
Methods: We therefore investigated the endocrine effects of adiponectin on bone metabolism using 12-week-old
male transgenic (Ad-Tg) mice with significant hyperadiponectinemia overexpressing human full-length adiponectin
in the liver.
Results: In Ad-Tg mice, the serum level of osteocalcin was significantly increased, but the levels of RANKL,
osteoprotegerin, and TRAP5b were not. Bone mass was significantly greater in Ad-Tg mice with increased bone
formation. In contrast, bone resorption parameters including the number of osteoclasts and eroded surface area
did not differ between Ad-Tg and their littermates.
Conclusions: These findings demonstrate that hyperadiponectinemia enhances bone formation in mice.
Background
Osteoporosis and related bone fractures are becoming
increasingly common in industrial countries due to
enhanced longevity [1,2]. Therefore, it is important
to know the factors that regulate bone mass, and to
develop effective therapeutic methods.
Adipose tissue is known to act as an energy-storing
o r g a nt h a ts e c r e t e sav a r i e t yo fb i o l o g i c a l l ya c t i v em o l e -
cules [3]. Adiponectin is one of the adipocytokines spe-
cifically and highly expressed in adipose tissue. It has
two subtypes: the full-length (predominant) form that is
distributed in the circulation, and the globular form [4].
This adipocytokine is present abundantly in plasma [5]
and plays important roles in the regulation of energy
homeostasis and insulin sensitivity [6,7], thus exerting
potent effects in various tissues.
It has been reported that the adiponectin signal is also
involved in bone homeostasis, since adiponectin and its
two related adiponectin receptor subtypes (AdipoR1 and
AdipoR2) have been identified in osteoblasts [8-10].
Although previous studies have examined the effect of
adiponectin on bone metabolisms, its physiological role
remains unclear [9-13].
Recently, we have successfully established two lines of
hyperadiponectinemic mice showing transgenic expres-
sion of human full-length adiponectin [14]. To test the
hypothesis that the level of circulating human full-length
adiponectin is positively correlated with bone metabo-
lism, the present study focused on characterizing its
endocrine effect in this strain of transgenic mice. We
demonstrated that hyperadiponectinemia enhances
osteogenesis through osteoblast formation.
Methods
Animals
Transgenic (Ad-Tg) mice overexpressing human full-
length adiponectin, driven by the human serum amyloid
component (SAP) promoter and with its expression lim-
ited to the liver, were generated as described previously
[14]. In each analysis, male Ad-Tg and their wild
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between heterozygous mice were compared. All the
mice were kept in plastic cages under standard labora-
tory conditions with a 12-h dark, 12-h light cycle, a con-
stant temperature of 23°C, and a humidity of 48%. The
mice were fed a standard rodent diet (CE-2; CLEA
Japan, Inc.) containing 25.2% protein, 4.6% fat, 4.4%
fiber, 6.5% ash, 3.44 Kcal/g, 2.5 IU vitamin D3/g, 1.09%
calcium, and 0.93% phosphorus with water ad libitum.
All animal experiments were performed on male mice at
12 weeks of age and were reviewed and approved by the
Animal Study Committee of Kurume University.
Skeletal morphology
There were 8 mice in each group (Lines 11 and 13 repre-
senting Ad-Tg mice, and their WT littermates): the right
femur was used for bone mineral density (BMD) and
bone mineral content (BMC) analysis, and the left tibia
for bone histomorphometric evaluation. A total of 24
mice were sacrificed and analyzed in this study. BMD
and BMC were measured in 24 femurs (8 femurs in each
mouse group) using a DCS-600EX-IIIR (Aloka). Twenty-
four tibiae (8 tibiae in each mouse group) were fixed in
70% ethanol, and the undecalcified bones were embedded
in glycolmethacrylate. Sections 3 μm thick were cut long-
itudinally in the proximal region of the tibiae, and stained
with toluidine blue. Histomorphometry was performed
with a semiautomatic image analysis system (Histometry
RT CAMERA, System Supply) linked to a light micro-
scope. The histomorphometric measurements were made
at ×400 using a minimum of 27-37 optical fields in the
secondary spongiosa area at the growth plate-metaphy-
seal junction. The bone was labeled with calcein twice,
with a 4-day interval between. The bone formation rate
and mineral apposition rate were measured at the proxi-
mal tibia after calcein injection (16 mg/kg, Dojin).
Nomenclature, symbols, and units are those recom-
mended by the Nomenclature Committee of the Ameri-
can Society for Bone and Mineral Research [15].
Blood chemistry
Blood was taken just before death, and the serum was
prepared. The level of human and mouse adiponectin
was measured using an ELISA kit for the human form
(Otsuka) and mouse form (AdipoGen). Mouse insulin
and leptin were determined using ELISA kits (Gen-
zyme). Serum levels of RANKL, osteocalcin (OC), OPG
and TRAP5b in serum were determined by ELISA with
a mouse osteocalcin EIA kit (Biomedical Technologies),
a mouse TRAP5b ELISA kit (Immunodiagnostic Sys-
tems), a mouse RANKL immunoassay kit (R&D Sys-
tems), and a mouse OPG immunoassay kit (R&D
Systems), respectively. Assays were performed in accor-
dance with the manufacturer’s recommendation.
Statistical analysis
All data are presented as mean ± S.D., and statistical
analysis was performed by ANOVA with Dunnett
adjustment. Differences were considered statistically sig-
nificant at P < 0.05.
Results
Transgenic (Ad-Tg) mice overexpressing human full-
length adiponectin in the liver
To examine the endocrine effect of human adiponectin
on bone metabolism, we analyzed two lines of 12-week-
old male Ad-Tg mice overexpressing human adiponectin
mRNA exclusively in the liver [14]. There was no
human adiponectin expression in other tissue: muscle,
visceral fat, spleen, or brain. The liver was histologically
normal, with levels of hepatic enzymes similar to those
in their WT littermates [14]. Ad-Tg mice in each line
grew normally, were fertile, and appeared healthy with
no gross histomorphological abnormalities. Measure-
ment of the serum level of human and mouse full-
length adiponectin in Ad-Tg mice using human and
mouse adiponectin-specific ELISA demonstrated signifi-
cant hyperadiponectinemia (Figure 1A, B). The plasma
level was elevated in human adiponectin Tg mice, indi-
cating a lack of negative feedback regulation. This find-
ing had also been noted in our previous study [14].
Although the precise mechanisms responsible for the
increase of endogenous mouse adiponectin in human
adiponectin Tg mice was not clarified in the present
study, it is conceivable that transgenic expression of adi-
ponectin results in an increase in the total level of circu-
lating adiponectin. The serum levels of leptin and
insulin did not differ significantly between Ad-Tg mice
and their WT littermates [14]. Thus, the Ad-Tg mice
u s e di nt h ep r e s e n ts t u d yw e r ec o n s i d e r e dt ob ea n
appropriate model for characterizing the endocrine
effect of human full-length adiponectin on bone
metabolism.
Serum levels of osteoblastic and osteoclastic markers
Firstly, we evaluated the levels of osteoblastic and osteo-
clastic markers in the serum of Ad-Tg and WT mice
(Table 1). The serum osteocalcin (OC) level has long
been used as a marker of osteoblast activity and new
bone formation [16,17]. We therefore measured the
level of OC in serum using a specific mouse OC ELISA
to evaluate osteoblast activity in WT and Ad-Tg mice.
The results showed that the serum OC level was signifi-
cantly higher in the Ad-Tg mice than in their WT
littermates, suggesting that osteoblastgenesis is increased
in Ad-Tg mice. To evaluate osteoclast activity, the
serum level of active TRAP5b, an enzyme that is
released from osteoclasts during bone resorption [18],
was examined and compared between Ad-Tg and WT
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level demonstrated no significant difference between
Ad-Tg and WT mice. To substantiate this further, we
next measured the serum levels of RANKL and OPG,
which are essential factors for osteoclast formation
[19,20]. In accord with the results for TRAP5b, the
serum levels of RANKL and OPG showed no significant
difference between Ad-Tg and Wt mice.
Histomorphometric analysis of Ad-Tg mice
To examine the role of endogenous human full-length
adiponectin in bone metabolism, we analyzed the long
bones of Ad-Tg mice and WT littermates at 12 weeks
of age. BMD and BMC of the whole femur were consis-
tently higher in Ad-Tg than in WT mice (Figure 2A, B).
Bone histomorphometric analysis was performed at
the proximal tibiae in Ad-Tg and WT mice (Table 2).
Bone volume was significanty increased due to the pre-
sence of human full-length adiponectin. Osteoblast sur-
face and osteoid surface, both representative of the
number of osteoblasts, were significantly greater in Ad-
Tg mice than in their WT littermates. In contrast, bone
resorption parameters including osteoclast number and
eroded surface area, did not differ between the two
types of mice. The mineral apposition rate, which
reflects the bone formation ability of individual osteo-
blasts, was significantly higher in Ad-Tg mice (Table 2).
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Figure 1 Serum levels of human (A) and mouse (B) full-length adiponectin in 12-week-old Ad-Tg and WT littermate mice. Data are
expressed as means (bars) ± S.D. (error bar), n = 8. ND, not detected. Significant difference from WT serum level, P < 0.05.
Table 1 Serum levels of osteocalcin, TRAP5b, RANKL and
OPG in 12-week-old Ad-Tg and WT littermate mice
WT Ad-Tg Line11 Ad-Tg Line13
Osteocaltin (ng/ml) 25.2 ± 1.1 27.8 ± 0.8** 27.7 ± 0.9**
TRAP5b (U/L) 2.2 ± 0.4 2.1 ± 0.3 2.3 ± 0.4
RANKL (pg/ml) 68.6 ± 7.2 82.0 ± 24.6 77.1 ± 29.1
OPG (ng/ml) 2226.9 ± 61.4 2251.5 ± 212.0 2521.9 ± 277.8
Data are expressed as means ± S.D. (n = 8). **Significant difference from WT
serum level, P < 0.05.
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the labeled sections in Ad-Tg mice was significantly
increased than that in the WT littermates. Thus, Ad-Tg
mice exhibited a high bone mass with increased bone
formation but normal osteoclast function.
Discussion
A few studies using Ad-Tg mice have assessed the role
of adiponectin in bone metabolism, but the results have
been conflicting [8,10,21]. Oshima et al. demonstrated
that transient overexpression of full-length mouse adi-
ponectin for 2 week by adenoviral infection in 8-week-
old C57BL/6J mice increased trabecular bone volume in
the distal femur compared with LacZ overexpressing
controls, with reduced number of osteoclasts in TRAP-
stained sections [8]. These results concurred with our
data in view of increased bone mass; however, they did
not report the serum levels of adiponectin, insulin, and
body weights. Shinoda et al. demonstrated no significant
differences in bone mass or turnover in 8-week-old
male Ad-Tg mice overexpressing globular-type adipo-
nectin specifically in the liver, compared to their WT lit-
termates [10]. In their study, no differences in BMD of
the femur, tibia, and vertebrae and no differences in
bone formation or resorption parameters were found in
Ad-Tg mice [10]. Recent studies have demonstrated
that the biological effect of adiponectin depends on its
molecular structure [22,23], suggesting that the full
effects of adiponectin on bone may be mediated by full-
length adiponectin, rather than the globular type.
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Figure 2 BMD (A) and BMC (B) of the entire femur were measured by DEXA. Data are expressed as means (bars) ± S.D. (error bar), n = 8.
Significant difference from WT mice, P < 0.05.
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mice had a significantly lower bone mineral content at 8
and 16 weeks of age, and that the femur neck peak load
was significantly lower in 8-week-old Ad-Tg mice of
both genders, in comparison with controls [21]. They
concluded that circulating adiponectin is a negative reg-
ulator of bone mineral and bone strength in mice. For
t h e i rs t u d y ,t h e yu s e dt r a n s g e n i cm i c ee x p r e s s i n g
a dominant mutation in the collagenous domain of adi-
ponectin, resulting in an increased level of adiponectin
complexes including full-length adiponectin; there was
also a sexual dimorphism in that females had signifi-
cantly higher circulating levels than males [21].
Two groups have previously reported the skeletal
changes in Ad KO mice. Shinoda et al. found no effect
on bone phenotype in Ad-knockout mice at 8 weeks of
age [10]. Williams et al. reported increases in the num-
ber of trabeculae and bone volume of the proximal tibia
at 14 week of age, but non-significant trends at 8 and
22 weeks, in Ad-knockout mice [24]. Interpreted
broadly, these studies gave similar results: wild-type and
Ad-knockout mice are similar in early life, but differ-
ences emerge in adulthood. Most investigators have
consistently demonstrated that Ad-knockout mice have
either spontaneous or diet-induced insulin resistance,
with hyperinsulinemia [25,26]. Thus, insulin resistance is
one potential explanation for the increased bone mass
in Ad-knockout mice.
The present study utilized 12-week-old male mice
overexpressing human full-length adiponectin specifically
in the liver and focused on the endocrine effects of this
molecule on bone, since human adiponectin is biologi-
cally active in mice [14,27]. A noteworthy finding was
that circulating human full-length adiponectin increased
bone mass and BMD in Ad-Tg mice by promoting osteo-
blast formation while osteoclast number remained nor-
mal. To our knowledge, similar findings have not been
reported previously.
According to the recent in vitro studies [8,10], we have
demonstrated that circulating human full-length adipo-
nectin increased bone formation in mice. In our previous
study, hyperadiponectinemia in the transgenic mice
resulted in suppression of fat accumulation and preven-
tion of premature death by a high-calorie diet, leading to
an increase of insulin sensitivity [14]. It is therefore con-
sidered that the increased osteoblastgenesis may have
resulted from the anabolic effects of insulin on bone. In
addition, an increase in osteoblast number could well be
the result of decreased oxidative stress that attenuates
the apoptosis of pre-existing osteoblasts [28]. The latter
interpretation is consistent with the evidence discussed
previously regarding the phenotype of age-related/Ad KO
mice with altered adiponectin expression.
In the present study, circulating human full-length
adiponectin did not affect the number of osteoclasts.
There was no significant difference in serum RANKL/
OPG levels between Ad-Tg mice and their WT litter-
mates. Bone histomorphometric and immunohistochem-
ical analysis consistently demonstrated normal osteoclast
function in Ad-Tg mice. As mentioned above, increased
insulin sensitivity was thought to be an important factor
for skeletal phenotype in our transgenic mice. The
major substrates of insulin are known to be closely
related insulin receptor substrate-1 and -2: IRS-1 and -2
[29]. Osteoclastic cells showed IRS-2 expression, but not
IRS-1 expression [30]. Intrinsic IRS-2 in osteoclastic
cells was not important for their differentiation, func-
tion, or survival despite the fact that IRS-2 and recep-
tors of insulin are expressed in these cells [31,32]. Thus,
these observations may explain why the circulating
human full-length adiponectin did not influence the
number of osteoclast in the transgenic mice.
Conclusions
We have demonstrated that elevation of the circulating
adiponectin level increases bone mass by activating bone
formation while normal osteoclast function is retained.
Our study confirms that hyperadiponectinemia positively
regulates osteogenesis, thus enhancing bone formation.
Abbreviations
Ad-Tg mice: Adiponectin Transgenic mice; WT: Wild Type; BMD: Bone
Mineral Density; BMC: Bone Mineral Content; OC: Osteocalcin; IRS: Insulin
Receptor Substrate
Table 2 Parameters for trabecular bone were measured
below the growth plate at the proximal metaphysis of
the tibia in Toluidine-Blue and calcein double-labeled
sections
WT Ad-Tg Line 11 Ad-Tg Line 13
BV/TV (%) 12.6 ± 2.7 16.1 ± 2.5* 17.3 ± 1.7**
Tb.N (/mm) 3.3 ± 0.3 3.9 ± 0.4* 3.9 ± 0.5*
OS/BS (%) 7.1 ± 4.1 17.7 ± 4.9** 15.4 ± 3.5*
O.Th (μm) 2.8 ± 0.2 3.3 ± 0.1** 2.8 ± 0.2
Ob.S/BS (%) 3.3 ± 2.8 7.4 ± 2.2* 9.3 ± 5.4**
N.Oc/B.Pm (/100 mm) 123.7 ± 41.1 112.2 ± 41.8 132.1 ± 60.7
Oc.S/BS (%) 1.0 ± 0.5 1.1 ± 0.7 1.4 ± 0.5
ES/BS (%) 2.7 ± 1.4 3.3 ± 1.5 4.4 ± 1.1
MAR (μm/day) 1.4 ± 0.2 1.7 ± 0.1** 1.6 ± 0.1*
MS/BS (%) 19.1 ± 3.2 33.1 ± 2.9** 26.8 ± 5.2*
BFR/BS (mm
3/mm
2/year) 0.09 ± 0.02 0.18 ± 0.03** 0.14 ± 0.03**
dLS/BS (%) 7.0 ± 1.0 20.7 ± 2.0** 14.6 ± 4.2**
BV/TV, bone volume/total tissue volume; Tb. N, trabecular number; OS/BS,
osteoid surface/bone surface; O.Th, osteoid thickness; Ob.S/BS, osteoblast
surface/bone surface; N.Oc/B.Pm, osteoclast number/bone perimeter; Oc.S/BS,
osteoclast surface/bone surface; ES/BS, eroded surface/bone surface; MAR,
mineral apposition rate; MS/BS (mineralization ratio), mineralizing surface/
bone surface; BFR/BS, bone formation rate/bone surface; dLS/BS, double
labeled surface/bone surface. Data are expressed as means ± S.D. of 8 bones/
group. *P < 0.05, **P < 0.01, significantly different from WT mice.
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